ARTICLE | Clinical News
Phytopharm's Phase II P45 results
January 18, 2001 8:00 AM UTC
Phytopharm (LSE:PYM) said that in a U.K. Phase II double-blind, placebo-controlled study of P45 to treat alopecia androgenica (male pattern baldness), evaluation of 69 of the 75 patients enrolled show...